血清Tracp5b诊断乳腺癌骨转移的临床价值

The clinical value of serum Tracp5b as a marker to diagnose bone metastases in breast cancer patients

目的:比较乳腺癌患者血清抗酒石酸酸性磷酸酶(Tracp5b)、糖类抗原-153(CA-153)及癌胚抗原(CEA)诊断乳腺癌骨转移的临床价值。方法:采用酶联免疫吸附法(ELISA)及电化学发光法检测18例健康女性、26例无骨转移的乳腺癌患者及32例乳腺癌骨转移患者的血清Tracp5b、CA-153及CEA水平。结果:乳腺癌骨转移组的血清Tracp5b水平较无骨转移组及健康对照组明显升高,差异有统计学意义(P<0.05);血清Tracp5b诊断乳腺癌骨转移的敏感性为78.13%,特异性为86.36%;CA-153的敏感性为37.50%,特异性为77.27%;CEA的敏感性为21.88%,特异性为84.09%;Tracp5b的敏感性较CA-153、CEA高,差异有统计学意义(P<0.05)。结论:Tracp5b可以作为诊断乳腺癌骨转移的血清标记物之一。

Objective：To compare the diagnostic value of serum tartrate-resistant acid phosphatase 5b （Tracp5b）, cancer antigen 153（CA-153） and carcino embryonic antigen（CEA） in patients with bone metastases of breast cancer. Methods：The serum levels of Tracp5b, CA-153 and CEA were determined by enzyme-linked immunosorbent assay and electrochemiluminescence in 26 breast cancer patients without bone metastases, 32 breast cancer patients with bone metastases and 18 healthy female adults. Results：The serum levels of Tracp5b in breast cancer patients with bone metastases were significantly higher than those in other two groups （P 〈 0.05）. The sensitivity and specificity of Tracp5b to bone metastases was 78.13% and 86.36%. The sensitivity and specificity of CA-153 to bone metastases was 37.50% and 77.27%, and those of CEA were 21.88% and 84.09%, respectively. The sensitivity of Tracp5b were significantly higher than those of CA-153 and CEA （P 〈 0.05）. Conelusion：Tracp5b is a useful serum marker to diagnose bone metastases in breast cancer patients.